Guangsheng Tang: Guansheng Zhonglin plans to introduce HuaXin Chuangtou and Huiyang investments to invest a total of no more than 200 million yuan.

Guangshengtang's announcement: The company's innovative drug holding subsidiary, Guangsheng Zhonglin, signed an investment letter of intent with Huaxin Chuangtou and Huiyang Investment. Huaxin Chuangtou, Huiyang Investment or their designated parties, as well as the co-investment parties mutually agreed upon by Guangsheng Zhonglin, intend to subscribe to Guangsheng Zhonglin's newly increased registered capital with cash not exceeding 2 billion yuan, based on a pre-investment valuation of not less than 2.5 billion yuan. After this transaction is completed, Guangsheng Zhonglin will still be a subsidiary controlled by the company and will not result in any changes to the company's consolidated financial statements.